Tetra Bio-Pharma (TBPMF) Stock Price, News & Analysis

Company Overview

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 185,753 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBPMF Stock Analysis - Frequently Asked Questions

How do I buy shares of Tetra Bio-Pharma?

Shares of TBPMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TBPMF
• CIK: N/A
• Web: www.tetrabiopharma.com
• Phone: (833) 977-7575
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A